Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Envisagenics

7 Disclosed Funding Rounds $5,575,000

0 Participating Investments


Therapeutics, Biotechnology, Machine Learning, Bioinformatics, Artificial Intelligence

Envisagenics seeks to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions.

New York, New York, United States, North America (US)

Organizations in New York in Therapeutics,
Organizations in New York in Biotechnology,
Organizations in New York in Machine Learning,
Organizations in New York in Bioinformatics,
Organizations in New York in Artificial Intelligence,
Organizations in New York in Therapeutics,
Organizations in New York in Biotechnology,
Organizations in New York in Machine Learning,
Organizations in New York in Bioinformatics,
Organizations in New York in Artificial Intelligence,
Organizations in United States in Therapeutics,
Organizations in United States in Biotechnology,
Organizations in United States in Machine Learning,
Organizations in United States in Bioinformatics,
Organizations in United States in Artificial Intelligence,
Organizations in North America in Therapeutics,
Organizations in North America in Biotechnology,
Organizations in North America in Machine Learning,
Organizations in North America in Bioinformatics,
Organizations in North America in Artificial Intelligence

Investors in New York in Therapeutics,
Investors in New York in Biotechnology,
Investors in New York in Machine Learning,
Investors in New York in Bioinformatics,
Investors in New York in Artificial Intelligence,
Investors in New York in Therapeutics,
Investors in New York in Biotechnology,
Investors in New York in Machine Learning,
Investors in New York in Bioinformatics,
Investors in New York in Artificial Intelligence,
Investors in United States in Therapeutics,
Investors in United States in Biotechnology,
Investors in United States in Machine Learning,
Investors in United States in Bioinformatics,
Investors in United States in Artificial Intelligence,
Investors in North America in Therapeutics,
Investors in North America in Biotechnology,
Investors in North America in Machine Learning,
Investors in North America in Bioinformatics,
Investors in North America in Artificial Intelligence

East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups), Greater New York Area (0 Investors) (0 Startups)

Founded date 04, 2014

Founders Maria Luisa Pineda, Martin Akerman

Operating Status Active

Funding Stage Seed

Last Funding Type Grant

Also known as Envisagenics

Company Type For Profit


Facebook Link

Twitter Link

LinkedIN Link

Wikipedia Link

Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.

Date Round Raised Lead
May, 22, 2018 Grant $1,500,000 National Institutes of Health
May, 01, 2018 Seed $1,000,000 -------
November, 28, 2017 Seed $2,400,000 Dynamk Capital
April, 13, 2017 Grant $350,000 -------
July, 01, 2016 Non-equity Assistance Undisclosed Grand Central Tech
August, 13, 2015 Grant $225,000 -------
July, 29, 2015 Debt Financing $100,000 -------

Envisagenics Investors (14)

Investor Lead? Round Participating Raise Date Partners
National Institutes of Health Yes Grant $1,500,000 May, 22, 2018 -------
Madrona Venture Group No Seed $1,000,000 May, 01, 2018 -------
M12 No Seed $1,000,000 May, 01, 2018 -------
Dolby Family Ventures No Seed $2,400,000 November, 28, 2017 -------
Third Kind Venture Capital No Seed $2,400,000 November, 28, 2017 -------
Dynamk Capital Yes Seed $2,400,000 November, 28, 2017 -------
Cosine No Seed $2,400,000 November, 28, 2017 -------
New York State No Seed $2,400,000 November, 28, 2017 -------
SV Angel No Seed $2,400,000 November, 28, 2017 -------
The Thiel Foundation No Grant $350,000 April, 13, 2017 -------
Grand Central Tech Yes Non-equity Assistance Undisclosed July, 01, 2016 -------
National Institutes of Health No Grant $225,000 August, 13, 2015 -------
Accelerate Long Island No Debt Financing $100,000 July, 29, 2015 -------
the Long Island Emerging technologies Fund (LIETF) No Debt Financing $100,000 July, 29, 2015 -------